124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison
about
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid CancerTumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.Dosimetry for radiopharmaceutical therapyMonte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PETStudy of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy.Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter.Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel sizeThe promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapyPreclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesPediatric papillary thyroid cancer: current management challengesThree-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.A 3D Monte Carlo Method for Estimation of Patient-specific Internal Organs Absorbed Dose for (99m)Tc-hynic-Tyr(3)-octreotide Imaging.Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images.A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.An analytical method for computing voxel S values for electrons and photons.Model-based versus specific dosimetry in diagnostic context: comparison of three dosimetric approaches.Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.An innovative iterative thresholding algorithm for tumour segmentation and volumetric quantification on SPECT images: Monte Carlo-based methodology and validation.
P2860
Q26829349-651689EC-3E4C-4AC4-923E-F88F0FAA4B54Q33427043-27E38546-39A8-4785-9B59-7ACF23E29DF5Q33665116-7FFFA554-10AA-4F29-95DF-DBD286D5D916Q33682852-1F327B88-85CE-46B7-8F52-F57987BBC574Q33768719-9F6E675A-47E9-41DC-891B-128A6ED75EE5Q33790290-5D81F815-3D82-4A95-A5F8-EA528842CF4FQ34013908-1D269F3A-DC61-4D6C-9F99-D5BA0AF018A0Q34117552-34E2CA53-BDFC-498B-A532-409332B497AEQ34166865-0547717D-0B9A-4FA7-ADE7-9E7FB6647E05Q34255798-A3A9F917-9929-41B9-95EE-F90EDFBA663AQ34281098-0DFFF278-F9CF-44C2-8232-5D925A8820DAQ35111985-8461E8FA-9176-4D19-971F-41BEE1A90753Q36297804-BFA59042-A9D1-483E-BA6B-AAB67531FB03Q36300599-1DDE65AD-7211-465F-8AC8-E764C6BD9BF5Q36302205-D2724CF1-101F-4FD9-B62F-F544E9149768Q36928870-AF05DF7A-18D1-4563-81FB-2086C3E6C1D7Q37551856-B4BF6363-2A84-471B-B010-EC9A176DAD99Q37864164-3CEFADCB-AC29-4104-BAD5-EA425F392F11Q39550058-6F5FEFFF-62C0-45A5-89C0-A660A8FE712EQ40036028-3CCC56CD-CAA4-471B-AA97-78FAC9F8AEC7Q42122579-2B2A6CFB-3D6D-4C45-8136-DA16D79CD2E1Q42763210-5827683E-78D5-4444-A8E5-1843783746C2Q42836462-D5484678-4B29-4BD6-BC01-06E8FC9663BAQ44673300-1FEA38A4-9E50-4421-9234-C5EE447063D0Q49153546-2E122E37-5F10-4492-AA46-C01B9DE8DAA4Q49827187-460458B3-EF40-4B77-8D41-D882364EBEE7Q50133955-8AE871CD-1FE9-467E-AAEC-3BE9F6412903Q50536307-6E9776F5-7FE7-40A1-A11A-DC96472FBFD2Q51542387-8A68BF33-CC80-4C8E-A633-5D6D321BDACC
P2860
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@ast
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@en
type
label
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@ast
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@en
prefLabel
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@ast
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@en
P2093
P2860
P1476
124I PET-based 3D-RD dosimetry ...... ng and methodologic comparison
@en
P2093
Caroline E Esaias
David T Chien
Marge E Ewertz
Martin A Lodge
Mehrbod S Javadi
Paul W Ladenson
Richard L Wahl
Steve Y Cho
P2860
P304
P356
10.2967/JNUMED.109.066738
P407
P577
2009-10-16T00:00:00Z